The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer.
Beinfeld M, Atlas SJ, Touchette D, McKenna A, Rind D, Pearson SD.
Beinfeld M, et al. Among authors: mckenna a.
J Manag Care Spec Pharm. 2021 Jun;27(6):797-804. doi: 10.18553/jmcp.2021.27.6.797.
J Manag Care Spec Pharm. 2021.
PMID: 34057394
Free PMC article.
ICER's annual policy summit is supported by dues from AbbVie, Aetna, America's Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmith …
ICER's annual policy summit is supported by dues from AbbVie, Aetna, America's Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, …